XML 128 R33.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Description of Business - Additional Information (Details) - Metacrine's FXR Program [Member] - Compounds | 9 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2023 | Mar. 31, 2023
Description Of Business And Summary Of Significant Accounting Policies [Line Items] |  |
Number of clinically tested compounds | 2 |
Number of discovery or preclinical compounds | 2,000 |
Metacrine, Inc. [Member] |  |
Description Of Business And Summary Of Significant Accounting Policies [Line Items] |  |
Number of clinically tested compounds |  | 2
Number of discovery or preclinical compounds |  | 2,000

X
- Definition Description of business and summary of significant accounting policies. + References No definition available. + Details
Name: | onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | onvo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of clinically tested compounds. + References No definition available. + Details
Name: | onvo_NumberOfClinicallyTestedCompounds
Namespace Prefix: | onvo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of discovery or preclinical compounds. + References No definition available. + Details
Name: | onvo_NumberOfDiscoveryOrPreclinicalCompounds
Namespace Prefix: | onvo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=onvo_MetacrinesFxrProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=onvo_MetacrineIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |